LEADER 05198nam 2200673Ia 450 001 9910810241003321 005 20200520144314.0 010 $a1-281-32099-4 010 $a9786611320997 010 $a0-470-75726-4 010 $a0-470-75724-8 035 $a(CKB)1000000000402898 035 $a(EBL)351209 035 $a(OCoLC)437218497 035 $a(SSID)ssj0000179344 035 $a(PQKBManifestationID)11184086 035 $a(PQKBTitleCode)TC0000179344 035 $a(PQKBWorkID)10138003 035 $a(PQKB)11138518 035 $a(MiAaPQ)EBC351209 035 $a(Au-PeEL)EBL351209 035 $a(CaPaEBR)ebr10232599 035 $a(CaONFJC)MIL132099 035 $a(EXLCZ)991000000000402898 100 $a20020103d2002 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aInhibitors in patients with haemophilia /$fedited by E.C. Rodriguez-Merchan, C.A. Lee 205 $a1st ed. 210 $aOsney Mead, Oxford ;$aMalden, MA $cBlackwell Science$dc2002 215 $a1 online resource (230 p.) 300 $aDescription based upon print version of record. 311 $a0-632-06477-3 320 $aIncludes bibliographical references and index. 327 $aInhibitors in Patients with Haemophilia; Contents; Contributors; Preface; Part 1: Haematology; 1 Natural history of inhibitors in severe haemophilia A and B: incidence and prevalence; 2 Characterization of inhibitors in congenital haemophilia; 3 Incidence and prevalence of inhibitors and type of blood product in haemophilia A; 4 Genetic basis of inhibitor development in severe haemophilia A and B; Part 2: Management of treatment; 5 Methods: plasmapheresis and protein A immunoadsorption; 6 Venous access in children with inhibitors; Part 3: Immune tolerance 327 $a7 Immune tolerance: high-dose regimen8 Immune tolerance: low-dose regimen; 9 Immune tolerance and choice of concentrates; 10 Immune tolerance: The North American Immune Tolerance Registry; Part 4: Medical management of bleeding episodes; 11 The treatment of bleeding episodes in children; 12 General medical management of bleeding episodes: haemarthroses, muscle haematomas, mucocutaneous bleeding and haematuria; 13 Life- and limb-threatening episodes and intracranial bleeds; Part 5: Inhibitors in haemophilia B, inhibitors in mild and moderate haemophilia A and acquired inhibitors to FVIII 327 $a14 Factor IX inhibitors and anaphylaxis15 Inhibitors in mild and moderate haemophilia A; 16 Acquired inhibitors to factor VIII; Part 6: Musculoskeletal issues; 17 Pathogenesis of musculoskeletal complications of haemophilia; 18 Orthopaedic management of haemarthroses; 19 Chemical synoviorthesis; 20 Radiosynoviorthesis in patients with haemophilia and inhibitors; 21 Musculoskeletal magnetic resonance imaging; 22 Treatment of iliopsoas haematomas and compartment syndromes in patients with haemophilia who have a circulating antibody 327 $a23 A rational approach to the treatment of haemophilic blood cyst (pseudotumour) in patients with inhibitors24 Haemophilia patients with inhibitors: a rheumatologist's point of view; 25 Rehabilitation of patients with haemophilia and inhibitors; 26 Physiotherapy in the management of patients with inhibitors; 27 Elective orthopaedic surgery in haemophilia patients with high-responding inhibitors; Part 7: General surgery; 28 General and emergency surgery in patients with high-responding inhibitors; 29 Dental extraction in patients with haemophilia and inhibitors; Part 8: Psychosocial issues 327 $a30 Psychosocial impact of inhibitors on haemophilia patients' quality of lifePart 9: General strategy for management of inhibitor patients; 31 General strategy for management of inhibitor patients (summary); 32 Immunoadsorption with anti-immunoglobulin antibodies using Ig-TheraSorb columns; 33 Standard, high and mega bolus doses of rVIIa or recombinant VIIa: comparison of three different treatment regimens; Index 330 $aEdited by an orthopaedic surgeon and a haematologist who are leading specialists in the treatment of haemophilia, Inhibitors in Patients with Haemophilia reviews the different haemostatic products and protocols for the control of bleeding and surgery in haemophilic patients with inhibitors. The book draws together in a single volume all of the clinical issues involved in the treatment of inhibitors from numerous specialists worldwide. It will be an invaluable resource for all those treating inhibitors in people with haemophilia. 606 $aHemophilia$xPathophysiology 606 $aHemophilia$xTreatment$xComplications 606 $aHemophilia$xImmunological aspects 615 0$aHemophilia$xPathophysiology. 615 0$aHemophilia$xTreatment$xComplications. 615 0$aHemophilia$xImmunological aspects. 676 $a616.1/572 701 $aRodriguez-Merchan$b E. C$0912313 701 $aLee$b Christine A$0912314 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910810241003321 996 $aInhibitors in patients with haemophilia$92094839 997 $aUNINA